Jefferies Group reissued their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report sent to investors on Tuesday. Jefferies Group currently has a $20.00 price target on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ Q2 2018 earnings at ($0.06) EPS, FY2018 earnings at ($0.98) EPS, FY2019 earnings at $0.85 EPS, FY2019 earnings at $0.81 EPS, FY2020 earnings at $0.59 EPS, FY2020 earnings at $0.60 EPS, FY2021 earnings at $1.00 EPS, FY2021 earnings at $0.96 EPS, FY2022 earnings at $1.91 EPS and FY2022 earnings at $2.07 EPS.
A number of other analysts have also weighed in on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, October 26th. Oppenheimer set a $26.00 target price on Vanda Pharmaceuticals and gave the company a buy rating in a research note on Sunday, October 29th. BidaskClub upgraded Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, December 22nd. ValuEngine upgraded Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, December 20th. Finally, Seaport Global Securities initiated coverage on Vanda Pharmaceuticals in a research report on Friday, January 19th. They issued a buy rating and a $20.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $21.43.
Shares of Vanda Pharmaceuticals (NASDAQ VNDA) opened at $17.10 on Tuesday. Vanda Pharmaceuticals has a 12 month low of $11.90 and a 12 month high of $18.99. The firm has a market capitalization of $767.90, a price-to-earnings ratio of -50.29 and a beta of 1.24.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative return on equity of 11.97% and a negative net margin of 9.43%. The company had revenue of $44.28 million during the quarter, compared to analyst estimates of $44.00 million. During the same period last year, the company posted $0.08 earnings per share. The firm’s quarterly revenue was up 15.8% compared to the same quarter last year. equities research analysts forecast that Vanda Pharmaceuticals will post -0.38 EPS for the current fiscal year.
In related news, SVP Gunther Birznieks sold 8,568 shares of Vanda Pharmaceuticals stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total value of $130,747.68. Following the completion of the sale, the senior vice president now directly owns 118,366 shares in the company, valued at $1,806,265.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO James Patrick Kelly sold 9,155 shares of Vanda Pharmaceuticals stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total value of $140,529.25. Following the completion of the sale, the chief financial officer now owns 144,721 shares of the company’s stock, valued at $2,221,467.35. The disclosure for this sale can be found here. Over the last quarter, insiders sold 209,483 shares of company stock valued at $3,205,205. Corporate insiders own 7.60% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. MetLife Investment Advisors LLC acquired a new stake in Vanda Pharmaceuticals in the fourth quarter worth about $308,000. Metropolitan Life Insurance Co. NY bought a new position in Vanda Pharmaceuticals during the fourth quarter worth about $221,000. Macquarie Group Ltd. boosted its holdings in Vanda Pharmaceuticals by 20.0% during the fourth quarter. Macquarie Group Ltd. now owns 2,268,691 shares of the biopharmaceutical company’s stock worth $34,484,000 after buying an additional 378,606 shares during the last quarter. TIAA CREF Investment Management LLC boosted its holdings in Vanda Pharmaceuticals by 5.1% during the fourth quarter. TIAA CREF Investment Management LLC now owns 446,482 shares of the biopharmaceutical company’s stock worth $6,787,000 after buying an additional 21,595 shares during the last quarter. Finally, Teachers Advisors LLC boosted its holdings in Vanda Pharmaceuticals by 0.8% during the fourth quarter. Teachers Advisors LLC now owns 702,028 shares of the biopharmaceutical company’s stock worth $10,671,000 after buying an additional 5,690 shares during the last quarter. Hedge funds and other institutional investors own 88.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2018/02/17/vanda-pharmaceuticals-vnda-buy-rating-reaffirmed-at-jefferies-group.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.